Sugi Predict

Sugi Predict / Compounds / SCHEMBL175272

SCHEMBL175272

SCHEMBL175272

O=C(O)Nc1ccccc1[N+](=O)[O-]

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.71
▸ KMT2A Q03164 1/20 0.71
▸ RAB9A P51151 3/20 0.62
▸ GAA P10253 2/20 0.62
▸ CYP3A4 P08684 1/20 0.62
▸ CYP2C9 P11712 1/20 0.62
▸ CYP2C19 P33261 1/20 0.62
▸ NPSR1 Q6W5P4 1/20 0.62
▸ KCNMA1 Q12791 1/20 0.61
▸ NPC1 O15118 3/20 0.60
▸ MAPT P10636 2/20 0.60
▸ L3MBTL1 Q9Y468 2/20 0.60
▸ ALDH1A1 P00352 2/20 0.59
▸ POLB P06746 2/20 0.59
▸ PHGDH O43175 1/20 0.59
▸ MAPK1 P28482 1/20 0.59
▸ CASP7 P55210 1/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ PDK1 Q15118 1/20 0.56
▸ PDK2 Q15119 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL113558 1.00 MEN1 (0.71) MEN1KMT2ARAB9AGAACYP3A4
SCHEMBL11332310 0.86 KMT2A (0.73) MEN1KMT2ARAB9AGAACYP3A4
SCHEMBL6857920 0.86 KMT2A (0.73) MEN1KMT2ARAB9AGAACYP3A4
SCHEMBL8925968 0.85 KMT2A (0.67) MEN1KMT2ARAB9AGAACYP3A4
SCHEMBL6377318 0.85 KMT2A (0.71) MEN1KMT2ARAB9AGAACYP3A4
SCHEMBL30388225 0.85 KMT2A (0.71) MEN1KMT2ARAB9AGAACYP3A4
SCHEMBL1745798 0.85 KMT2A (0.71) MEN1KMT2ARAB9AGAACYP3A4
SCHEMBL11551428 0.84 POLB (0.75) MEN1KMT2ARAB9AGAACYP3A4
SCHEMBL169338 0.84 POLB (0.54) MEN1KMT2ARAB9AGAACYP3A4
SCHEMBL169339 0.84 POLB (0.54) MEN1KMT2ARAB9AGAACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190043731-A1 TWO-STAGE BAKE PHOTORESIST WITH RELEASABLE QUENCHER INTEL CORPORATION 2019-02-07 — — US claimed
WO-2017176282-A1 TWO-STAGE BAKE PHOTORESIST WITH RELEASABLE QUENCHER INTEL CORPORATION (US) 2017-10-12 — — WO claimed
EP-1317430-B1 (2-AZABICYCLO [2.2.1]HEPT-7-YL)METHANOL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS MERCK PATENT GMBH (DE) 2005-05-18 — — EP claimed
US-20040039045-A1 (2-azabicyclo[2.2.1]hept-7yl) methanol derivatives as nicotinic acetylcholine receptor agonists MERCK PATENT GMBH (DE) 2004-02-26 — — US claimed
EP-1334102-A1 BOMBESIN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2003-08-13 — — EP claimed
WO-2002040475-A1 BOMBESIN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2002-05-23 — — WO claimed
WO-2000069878-A1 UNIVERSAL SOLID SUPPORTS SUITABLE FOR THE SYNTHESIS OF NUCLEIC ACIDS NGO NAM Q (US) 2000-11-23 — — WO claimed
CN-118647614-A Crystalline forms of N- (6-amino-5-methylpyridin-3-yl) -2- (benzo [ d ] thiazol-5-yl) -5-methylpiperidin-1-yl) -2-oxoacetamide, pharmaceutical compositions and methods of use 探戈医药股份有限公司 2024-09-13 — — CN disclosed
US-20240208898-A1 ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-06-27 — — US disclosed
US-11955343-B2 Two-stage bake photoresist with releasable quencher INTEL CORPORATION (US) 2024-04-09 — — US disclosed
US-20240071917-A1 ADVANCED LITHOGRAPHY AND SELF-ASSEMBLED DEVICES INTEL CORP (US) 2024-02-29 — — US disclosed
EP-4320073-A1 BIOORTHOGONAL REACTION SUITABLE FOR CLICK/UNCLICK APPLICATIONS Dana-Farber Cancer Institute, Inc. (US) 2024-02-14 — — EP disclosed
EP-4313013-A2 ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS Dana-Farber Cancer Institute, Inc. (US) 2024-02-07 — — EP disclosed
US-6010681-A CHELATE COMPOUND NYCOMED SALUTAR, INC. (US) 2000-01-04 — — US disclosed
WO-1998041866-A1 A HIGH THROUGHPUT ASSAY USING FUSION PROTEINS MERCK & CO., INC. (US) 1998-09-24 — — WO disclosed
WO-1998018781-A9 FUSED 2,4-PYRIMIDINEDIONE COMBINATORIAL LIBRARIES, THEIR PREPARATION AND THE USE OF FUSED 2,4-PYRIMIDINEDIONES DERIVATIVES AS ANTIMICROBIAL AGENTS — 1998-08-20 — — WO disclosed
WO-1998018781-A2 FUSED 2,4-PYRIMIDINEDIONE COMBINATORIAL LIBRARIES, THEIR PREPARATION AND THE USE OF FUSED 2,4-PYRIMIDINEDIONES DERIVATIVES AS ANTIMICROBIAL AGENTS VERSICOR, INC. (US) 1998-05-07 — — WO disclosed
EP-0755269-A1 CONTRAST AGENTS NYCOMED SALUTAR, INC. (US) 1997-01-29 — — EP disclosed
WO-1995028967-A1 CONTRAST AGENTS NYCOMED SALUTAR INC (US) 1995-11-02 — — WO disclosed
US-5382637-A Solid state chain extension polymerization between Lewis acid oligomers and deblocked Lewis bases INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 1995-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039045-A1 (2-azabicyclo[2.2.1]hept-7yl) methanol derivatives as nicotinic acetylcholine receptor agonists CHRNA1, CHRNA10, CHRNB1 MEN1 2964/4885KMT2A 1979/4885RAB9A 1504/4885
US-20240208898-A1 ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS ENO1, HIF1A, HIF1AN MEN1 535/4885KMT2A 1870/4885RAB9A 3234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.